2023 World Conference on Lung Cancer (Posters)-P2.16. Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC

P2.16. Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC - PDF(Abstract)

Back to course

Pdf Summary

SCLC, also known as small cell lung cancer, is an aggressive form of lung cancer with limited treatment options and a poor prognosis. However, immunotherapy has shown promise in improving clinical outcomes for SCLC patients. Atezolizumab and durvalumab, anti-PD-L1 antibodies, have already been approved for first-line treatment. Serplulimab, an anti-PD-1 antibody, has also shown improved overall survival compared to chemotherapy alone in ES-SCLC. <br /><br />In this study, researchers are exploring the role of sintilimab, another anti-PD-1 antibody, in the treatment of previously untreated ES-SCLC patients. The study is a single-center, single-arm, investigator-initiated phase II study. The primary objective is to evaluate the progression-free survival (PFS) rate at 12 months using RECIST 1.1 criteria as assessed by the investigator. Secondary objectives include assessing PFS, overall survival (OS), objective response rate (ORR), quality of life, and safety. Additionally, the researchers will explore potential biomarkers in blood and tumor tissue.<br /><br />Patients in the study will undergo radiographic imaging at baseline, every 6 weeks after drug administration, and every 9 weeks after 24 weeks until disease progression or unacceptable toxicity occurs. Adverse events will be monitored throughout the trial and graded according to CTCAE v5.0.<br /><br />The study holds promise for improving the treatment options for ES-SCLC patients and understanding the role of sintilimab in this setting. The results may also help identify potential biomarkers for future research. This research falls under Track 13, which focuses on small cell lung cancer and neuroendocrine tumors, and is categorized as a clinical trial in progress.

Asset Subtitle

Mengqing Xie

Meta Tag

Speaker Mengqing Xie

Topic SCLC & Neuroendocrine Tumors: Trials in Progress

Keywords

SCLC

small cell lung cancer

immunotherapy

Atezolizumab

durvalumab

Serplulimab

ES-SCLC

sintilimab

biomarkers

clinical trial in progress